Prevalence of the BRCA1 founder mutation c.5266dupin Brazilian individuals at-risk for the hereditary breast and ovarian cancer syndrome

Hereditary Cancer in Clinical Practice

Patricia Ashton-Prolla⁴  Roberto Giugliani⁵  Patrícia Koehler-Santos⁵  Maira Caleffi¹  Aishameriane Schmidt⁶  Suzi A Camey⁶  Sara Hamaguchi⁷  Danielle R Cunha⁷  Carlos A Moreira-Filho⁸  Aline S Moreira²  Miguel AM Moreira²  Fernando R Vargas³  Patrícia Izetti⁴  Ingrid P Ewald⁵ 

[1] Núcleo Mama Moinhos. Associação Hospitalar Moinhos de Vento. Rua Ramiro Barcelos 910, 11°. Andar. 90035-001, Porto Alegre, Brazil;Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz (IOC-FIOCRUZ), Fundação Oswaldo Cruz, Av. Brasil 4365. Pavilhão Leônidas Deane (Pav. 26) - 1° andar- sala 110 21040-900 - Rio de Janeiro, Brazil;Divisão de Genética, INCA (Instituto Nacional de Câncer). Rua André Cavalcanti, 37 - Centro 20231-050. Rio de Janeiro, Brazil;Programa de Pós-Graduação em Genética de Biologia Molecular, Universidade Federal do Rio Grande do Sul. Av. Bento Gonçalves, 9500 - Prédio 43323M. 91501-970 - Caixa Postal 15053 - Porto Alegre, RS, Brasil;Programa de Pós-Graduação em Medicina: Ciências Médicas, Universidade Federal do Rio Grande do Sul. Rua Ramiro Barcelos 2400, 2° andar. 90035-903. Porto Alegre, Brazil;Instituto de Matemática, Universidade Federal do Rio Grande do Sul. Av. Bento Gonçalves 9500 Prédio 43-111 - Agronomia. Caixa Postal 15080, Porto Alegre, Brazil;Instituto Israelita de Ensino e Pesquisa Albert Einstein. Av. Albert Einstein 627, 05651-901. São Paulo, Brazil;Departamento de Pediatria, Faculdade de Medicina da Universidade de São Paulo. Av. Dr. Enéas Carvalho de Aguiar 647. 05403-900, São Paulo, Brazil

关键词: BRCA2 gene;    BRCA1 gene;    Founder mutations;    Hereditary breast and ovarian cancer Syndrome;    Hereditary breast cancer;   

Others  :  806546
DOI  :  10.1186/1897-4287-9-12

 received in 2011-04-25, accepted in 2011-12-20,  发布年份 2011

【 摘 要 】

About 5-10% of breast and ovarian carcinomas are hereditary and most of these result from germline mutations in the BRCA1 and BRCA2 genes. In women of Ashkenazi Jewish ascendance, up to 30% of breast and ovarian carcinomas may be attributable to mutations in these genes, where 3 founder mutations, c.68_69del (185delAG) and c.5266dup (5382insC) in BRCA1 and c.5946del (6174delT) in BRCA2, are commonly encountered. It has been suggested by some authors that screening for founder mutations should be undertaken in all Brazilian women with breast cancer. Thus, the goal of this study was to determine the prevalence of three founder mutations, commonly identified in Ashkenazi individuals in a sample of non-Ashkenazi cancer-affected Brazilian women with clearly defined risk factors for hereditary breast and ovarian cancer (HBOC) syndrome. Among 137 unrelated Brazilian women from HBOC families, the BRCA1c.5266dup mutation was identified in seven individuals (5%). This prevalence is similar to that encountered in non-Ashkenazi HBOC families in other populations. However, among patients with bilateral breast cancer, the frequency of c.5266dup was significantly higher when compared to patients with unilateral breast tumors (12.1% vs 1.2%, p = 0.023). The BRCA1 c.68_69del and BRCA2 c.5946del mutations did not occur in this sample. We conclude that screening non-Ashkenazi breast cancer-affected women from the ethnically heterogeneous Brazilian populations for the BRCA1 c.68_69del and BRCA2 c.5946del is not justified, and that screening for BRCA1c.5266dup should be considered in high risk patients, given its prevalence as a single mutation. In high-risk patients, a negative screening result should always be followed by comprehensive BRCA gene testing. The finding of a significantly higher frequency of BRCA1 c.5266dup in women with bilateral breast cancer, as well as existence of other as yet unidentified founder mutations in this population, should be further assessed in a larger well characterized high-risk cohort.

【 授权许可】

   
2011 Ewald et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Instituto Nacional do Cancer: [http://www.inca.gov.br] webciteBrazil. 2011.
• [2]Ashton-Prolla P, Palmero EI, Roth FL: Mastologia: Genética e Câncer de Mama. In Ginecologia Baseada em Evidências. 2nd edition. Edited by Silveira GPG. Atheneu; 2008:519-529.
• [3]Gonçalves ATC, Jobim PFC, Vanacor R, et al.: Câncer de mama: mortalidade crescente na Região Sul do Brasil entre 1980 e 2002. Cadernos Saúde Pública 2007, 23:1785-1790.
• [4]Allain DC: Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn 2008, 10(5):383-95.
• [5]Online Mendelian Inheritance in Man [http://omim.org/entry/113705] webcite 2011.
• [6]Ford D, Easton DF, Bishop DT, Narod SA, et al.: Risks of cancer in BRCA1 mutation carriers. Lancet 1994, 343:692-695.
• [7]Walsh T, Casadei S, Coats KH, et al.: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295:1379-1388.
• [8]Tonin P, Weber B, Offit K, et al.: Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996, 2:1179-1183.
• [9]Warner E, Heisey RE, Goel V, et al.: Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. Can Fam Physician 1999, 45:104-112.
• [10]Bogdanova NV, Rogov YI, et al.: High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin Genet 2010, 78(4):364-72.
• [11]Uglanitsa N, Oszurek O, Uglanitsa K, et al.: The contribution of founder mutations in BRCA1 to breast cancer in Belarus. J Clin Genet 2010, 78(4):377-80.
• [12]Sarantaus L, Arason A, et al.: Haplotype analysis in Icelandic and Finnish BRCA2999del5 breast cancer families. Eur J Hum Genet 2001, 9:773-779.
• [13]Hartmann C, John AL, Klaes R, et al.: Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. Hum Mutat 2004, 24(6):534.
• [14]Lawrence WF, Peshkin BN, Liang W, et al.: Cost of Genetic Counseling and Testing for BRCA1 and BRCA2 Breast Cancer Susceptibility Mutations. Cancer Epidemiol Biomarkers Prev 2001, 10(5):475-481.
• [15]Gomes MC, Costa MM, Borojevic R, et al.: Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007, 103(3):349-53.
• [16]Vargas FR, Bines J, et al.: BRCA1 mutations in Brazilian patients. Genetics and Molecular Biology 2004, 27:500-504.
• [17]Simon SD, Molina A, Moreira-Filho CA: Mutations of BRCA1/2 genes in Brazil. In ASCO Annual Meeting. New Orleans, USA; 2003.
• [18]Hamel N, Feng BJ, Foretova L, et al.: On the origin and diffusion of BRCA1c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011, 19(3):300-6.
• [19]ASCO Subcommittee on Genetic Testing for Cancer Susceptibility: Statement of the American Society of Clinical Oncology: Genetic Testing for Cancer Susceptibility. J Clin Oncol 1996, 14:1730-1736.
• [20]Frank TS, Deffenbaugh AM, Reid JE, et al.: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002, 20:1480-1490.
• [21]Myriad Genetics, Laboratories and Pharmaceuticals, Inc[http://www.myriad.com] webcite 2007.
• [22]Couch Modified Mutation Prediction Model [http://www.afcri.upenn.edu/itacc/penn2/] webcite 2011.
• [23]Puregene genomic DNA purification method [http:/ / www1.qiagen.com/ Products/ GenomicDnaStabilizationPurification / GentraPuregeneBloodKit] webcite 2011.
• [24]Weitzel JN, Lagos VI, Cullinane CA, et al.: Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 2007, 297(23):2587-2595.
• [25]Abeliovich D, Kaduri L, Lerer I, et al.: The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997, 60(3):505-514.
• [26]Jeffery P, Struewing MD, Hartge Patricia, et al.: The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997, 336:1401-1408.
• [27]Weitzel JN, Lagos V, Blazer KR, et al.: Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005, 14(7):1666-71.
• [28]Breast Cancer Information Core (BIC) database[http://research.nhgri.nih.gov/bic/] webcite 2011.
• [29]Couch FJ, Weber BL: Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core Hum Mutat 1996, 8:8-18.
• [30]Backe J, Hofferbert S, Skawran B, et al.: Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol Oncol 1999, 72:402-406.
• [31]Tommasi S, et al.: BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. Mutat Res 2005, 578:395-405.
• [32]Sokolenko AP, Rozanov ME, Mitiushkina NV, et al.: Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam Cancer 2007, 6:281-286.
• [33]Peixoto A, Salgueiro N, Santos C, et al.: BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. Fam Cancer 2006, 5(4):379-387.
• [34]Esteban-Cardeñosa E, Bolufer Gilabert P, de Juan Jimenez I, et al.: Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern. Spain population. Breast Cancer Res Treat 2010, 121(1):257-60.
• [35]Diez O, Gutiérrez-Enríquez S, Balmaña J, et al.: Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Fam Cancer 2010, 187-91.
• [36]Llort G, Munoz CY, Tuser MP, et al.: Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Hum Mutat 2002, 19:307.
• [37]Infante M, Duran M, Esteban-Cardeñosa E, et al.: High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-Leon (central Spain). J Hum Genet 2006, 51:611-617.
• [38]Jara L, Ampuero S, Santibáñez E, et al.: BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 2006, 166:36-45.
• [39]Salazar R, Cruz-Hernandez JJ, Sanchez-Valdivieso E, et al.: BRCA1-2 mutations in breast cancer: identification of nine new variants of BRCA1-2 genes in a population from central Western Spain. Cancer Lett 233:172-177.
• [40]Torres D, Rashid MU, Gil F, et al.: High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 2007, 103:225-232.
• [41]Antoniou AC, Pharoah PD, Narod S, et al.: Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42:602-603.
• [42]Esteves VF, Thuler LC, Amêndola LC, et al.: Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil. Braz J Med Biol Res 2009, 42(5):453-7.
• [43]da Costa EC, Vargas FR, Moreira AS, et al.: Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome. Cancer Genet Cytogenet 2008, 184(1):62-66.
• [44]Carvalho-Silva DR, Santos FR, Rocha J, et al.: The phylogeography of Brazilian Y-chromosome lineages. Hum Genet 2001, 68:281-286.
• [45]Cardeñosa E, Bolufer Gilabert P, de Juan Jimenez I, et al.: BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population. Breast Cancer Res Treat 121(1):257-60.
• [46]Diez O, Gutiérrez-Enríquez S, Balmaña J: Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area:implications for genetic testing. Fam Cancer 2010, 9(2):187-91.
• [47]Loman N, Johannsson O, Kristoffersson U, et al.: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Nat Can Inst 2003, 93(16):1215-1223.
• [48]Weitzel JN, Robson M, Pasini B, et al.: A comparison of bilateral breast cancers in BRCA carriers. Can Epid Bio Prev 2004, 14(6):1534-1537.
• [49]Gershani-Baruch R, Dagan E, Fried G, et al.: BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer. Eur J HumGenet 1999, 7:833-836.
• [50]Rodriguez RC, Esperon AA, Ropero R, et al.: Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. Fam Cancer 2008, 7:275-279.
• [51]Alves-Silva J, da Silva Santos M, Guimaraes PE, et al.: The ancestry of Brazilian mt DNA lineages. Am J Hum Genet 67:444-461.
• [52]Parra FC, Amado RC, Lambertucci JR, et al.: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003, 100:177-182.
• [53]Wang S, Lewis CM, Jakobsson M, et al.: Genetic variation and population structure in native Americans. PLoS Genet 2007, 3(11):e185.